在膝关节骨关节炎中识别潜在的药物标:可药物基因组的见解
Chiyun Sun1,2, Ruikang Liu1,3, Weiming Fan1,2
1Beijing University of Chinese Medicine, Beijing, China.
Rejuvenation research
|December 29, 2025
概括
这项研究使用先进的遗传分析确定了16种膝关节骨关节炎 (KOA) 的潜在药物标. 发现身体质量指数 (BMI) 可以调节MAPK3对KOA风险的影响,这表明了新的治疗途径.
科学领域:
- 遗传学和生物信息学 遗传学和生物信息学
- 骨关节炎研究 骨关节炎研究
- 药物基因组学 药物基因组学
背景情况:
- 膝关节关节炎 (KOA) 是一种具有有限有效药物点的衰弱性疾病.
- 目前对KOA的治疗策略往往侧重于症状管理,而不是疾病修改.
研究的目的:
- 确定膝关节骨关节炎 (KOA) 的新型,可用药物的治疗点.
- 通过先进的遗传分析,研究已识别的目标的潜在作用机制和组织特异性影响.
主要方法:
- 使用孟德尔随机化 (MR) 分析,包括药物向MR,单细胞MR和中介MR.
- 综合表达量特征位点 (eQTL) 数据,蛋白质量特征位点 (pQTL) 数据和全基因组关联研究 (GWAS).
- 应用了基因信息空间绘图 (gsMap) 框架与空间转录组学数据.
主要成果:
- 从外围和中心组织中确定了16个KOA的潜在治疗点.
- 在蛋白质层面验证了MAPK3和MARK3;MAPK3与KOA.表现出一种保护性关联.
- 单细胞MR显示了LY6D,MAPK3和TGFA的细胞类型特定关联.
- 中介分析表明,身体质量指数 (BMI) 中介于MAPK3和KOA.之间的因果效应的16.6%.
- GsMap分析突出显示,KOA信号在软骨,肺和大脑组织中的丰富.
结论:
- 从综合基因分析中提出了16个膝关节骨关节炎 (KOA) 的潜在治疗点.
- 突出了BMI在MAPK3-KOA协会中的调解作用,表明了一个潜在的机制.
- 强调需要进一步实验验证KOA病变发生过程中已识别的标和机制.
相关概念视频
Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K


